The iron chelator deferiprone improves the phenotype in a mouse model of tauopathy
Manuscript Number:
20-0551R1
Author(s):
Paul A. Adlard, Ashley I. Bush, Larissa Lago, Stuart D. Portbury, Shalini S. Rao
Disclosures
Paul A. Adlard
Consulting Fees:
I am a paid consultant to Alterity Therapeutics. This company is focussed on the use of metal modulation for the treatment of neurodegenerative diseases. This company had no role in this manuscript.
Equity:
I am a shareholder (and also have stock options) in Alterity Therapeutics. This company is focussed on the use of metal modulation for the treatment of neurodegenerative diseases. This company had no role in this manuscript.
Ashley I. Bush
Consulting Fees:
Consulting fees from Collaborative Medicinal Development Pty Ltd
Equity:
Equity in Alterity Ltd, Cogstate Ltd, Mesoblast Ltd, Brighton Biosciences Ltd, profit share in Collaborative Medicinal Development Pty Ltd